Stifel: 'ALKS Shares Should Get a Boost on CNTA Disclosure'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Truist Securities Comments on Centessa Pharmaceuticals (CNTA) Amid 18pct Drop
November 5, 2025 8:03 AM ESTTruist Securities analyst Danielle Brill reiterated a Buy rating and $30.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).
The analyst comments "CNTA shared the highly anticipated preliminary Ph 2a data with ORX750 in narcolepsy type 1 & 2 (NT1/NT2) and idiopathic hypersomnia (IH) this morning.... More
